Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01676701 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 8
- Enrollment target
NCT01676701: Clinical Trial Phase 3 study, sponsored by Eli Lilly and Company.
NCT01676701 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 8 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01676701, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the serum concentration of tabalumab after the administration using either prefilled syringe or auto-injector after the initial loading dose and after 12 weeks of treatment. Treatment period is followed by 40 weeks optional safety extension.
Interventions
- DRUG Tabalumab Auto-Injector
- DRUG Tabalumab Prefilled Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
Why NCT01676701 stopped before completion
NCT01676701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Tabalumab Auto-Injector is the first listed.
NCT01676701 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01676701 about?
NCT01676701 is a clinical study titled "Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)". The purpose of this study is to evaluate the serum concentration of tabalumab after the administration using either prefilled syringe or auto-injector after the initial loading dose and after 12 weeks of treatment. Treatment period is followed by 40 weeks optional safety extension.
What is the current status of trial NCT01676701?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 8 participants. The study started on 2012-09. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01676701?
The interventions under investigation include: Tabalumab Auto-Injector (DRUG), Tabalumab Prefilled Syringe (DRUG).
Who is sponsoring clinical trial NCT01676701?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01676701's enrollment target sits among peer trials
8 1993rd of 2000 higher than 6 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia